Navigation Links
NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
Date:3/4/2009

elieves that NVC-422 may deliver the same or better efficacy as currently used antibiotics without giving rise to resistant bacteria. In past in-vitro studies, NVC-422 has shown a broad therapeutic index with broad spectrum activity against bacteria of all types, including multidrug resistant species, shedding viruses including adenoviruses and herpes viruses, yeasts and fungi. In addition, NVC-422 has previously shown, in-vivo, to be safe at expected therapeutic doses in the nose, bladder, wounds and eye. NVC-422 is protected by U.S. Patent #7,462,361 until 2026. In addition to Alcon's development in the eye, NovaBay has taken NVC-422 into Phase II human trials for infections in the nose and bladder and expects to begin a Phase II trial for the treatment of skin infections, including those caused by MRSA (Methicillin resistant Staphylococcus aureus), in 2009.

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a clinical stage biopharmaceutical company developing first-in-class, novel, synthetic anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections without developing resistance. NovaBay has entered into a licensing and research collaboration agreement with Alcon, Inc. for use of the Aganocide compounds in the eye, ear and sinus, and in contact lens solutions. NovaBay(R) and Aganocide(R) are trademarks of NovaBay Pharmaceuticals, Inc. For more information on NovaBay, visit www. novabaypharma.com.

Cautionary Information Regarding Forward-Looking Statements

The statements in this press release regarding the potential efficacy of NVC-422 and NovaBay's expectation to begin a Phase II trial for the treatment of skin infections in 2009 are forward-looking statements. These statements are subject to risks and uncertainties that could cau
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock
2. NovaBay announces third quarter 2007 financial results
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Focus, a non-profit organization striving to improve the living ... Corridor region, is releasing results for its 2013 Creative ... May 23rd at 10:30 a.m. The survey follows ... The survey is a critical component to the organizations’ ... and retain people of diverse backgrounds, cultures and beliefs ...
(Date:5/21/2013)... Colo. (May 21, 2013) A paper recently published ... and co-written by physicians and scientists at the University ... genetic risk factor for pulmonary fibrosis can be used ... disease. , Researchers looked at a fairly common variant ... a component of the mucous produced by the bronchial ...
(Date:5/21/2013)... for scientific and technological research So Paulo Research Foundation, ... an investment estimated in US$ 680 million to support ... period of up to eleven years, subject to continuation ... Funding for the 17 RIDCs will come from FAPESP ... personnel, and infrastructure). Host institutions will participate in a ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Today, Zane ... HSA and FSA accounts. Zane Benefits, which provides ... benefits, is the leader in defined contribution ... arrangements . , According to Zane Benefits’ website, the ... was signed into law in 2010 and impacts many ...
(Date:5/21/2013)... 21, 2013 While North Carolina is ... comprehensive travel guides. Brunswick Plantation & Golf Resort is ... include access to 27 holes of "Top10" championship golf. ... North Carolina, knowing the Top 10 from ... away the overwhelming task of selecting the course to ...
Breaking Medicine News(10 mins):Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Brunswick Plantation & Golf Resort Named in Top 10 Golf Resorts in North Carolina 2
... Medicine at Harvard Medical School and Beth Israel Deaconess ... Lectureship at the annual meeting of the Federation of ... month in Washington, DC. Named in honor of ... for radioimmunoassay led to discoveries that have helped to ...
... By Maureen Salamon HealthDay Reporter , THURSDAY, ... N.C., was in her early forties when she developed anorexia ... "In the middle of a disorder like that, you ... you," she said. Luckily, Hodgin sought the care of ...
... people develop diabetes because they don,t have enough pancreatic beta ... sugar levels. But what if other cells ... cells? Could we potentially cure diabetes? Researchers ... an important step in that direction. They report in the ...
... PHILADELPHIA Black cardiac arrest victims are more likely ... a large black population than when they,re brought to hospitals ... research from the University of Pennsylvania School of Medicine. The ... American Heart Journal . The Penn team found that, ...
... Tierney, M.D., president and CEO of the Regenstrief Institute ... Indiana University School of Medicine, received a 2011 Distinguished ... and Education Meeting on April 28 in Washington, DC. ... Achievement and Contribution to Clinical and Translational Science. He ...
... Vision and Ophthalmology (ARVO) is pleased to announce its 2011 ... the ARVO 2011 Annual Meeting, May 1 5, in ... MD, PhD, FARVO, Mildred Weisenfeld Award for Excellence in Ophthalmology: ... James T. Rosenbaum, MD, FARVO, Cogan Award: Andrew J. Fischer, ...
Cached Medicine News:Health News:Christos Mantzoros honored by Federation of the American Societies for Experimental Biology 2Health News:Bringing Partner Into Anorexia Treatment May Aid Recovery 2Health News:Bringing Partner Into Anorexia Treatment May Aid Recovery 3Health News:Researchers discover mechanism that could convert certain cells into insulin-making cells 2Health News:Black cardiac arrest patients more likely to be admitted to hospitals with lowest survival rates 2Health News:Tierney named 2011 Clinical and Translational Research Distinguished Investigator 2Health News:2011 ARVO Award recipients honored at annual meeting 2Health News:2011 ARVO Award recipients honored at annual meeting 3
(Date:5/21/2013)... May 21, 2013 Reaching a critical milestone ... National Association of Boards of Pharmacy ® (NABP ... domain suffix has passed the Internet Corporation for Assigned ... launch the .PHARMACY gTLD by the end of 2013, ... online pharmacies and related entities that are located in ...
(Date:5/21/2013)... -- Concord Medical Services Holdings Limited ("Concord Medical" or ... specialty hospital management solution provider and operator of the ... China and the parent of Chang,an Hospital, today reported ... ended March 31, 2013 [1] . First ... consists of net revenues generated from the network business ...
(Date:5/21/2013)... LAWRENCE, Mass. , May 21, 2013  NxStage ... manufacturer of innovative dialysis products, today announced that it ... home, critical care and in-center products to DaVita, the ... (Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO ) For the ... the United States , NxStage has executed a ...
Breaking Medicine Technology:NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 2NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 3Concord Medical Reports First Quarter 2013 Financial Results 2Concord Medical Reports First Quarter 2013 Financial Results 3Concord Medical Reports First Quarter 2013 Financial Results 4Concord Medical Reports First Quarter 2013 Financial Results 5Concord Medical Reports First Quarter 2013 Financial Results 6Concord Medical Reports First Quarter 2013 Financial Results 7Concord Medical Reports First Quarter 2013 Financial Results 8Concord Medical Reports First Quarter 2013 Financial Results 9Concord Medical Reports First Quarter 2013 Financial Results 10Concord Medical Reports First Quarter 2013 Financial Results 11Concord Medical Reports First Quarter 2013 Financial Results 12Concord Medical Reports First Quarter 2013 Financial Results 13NxStage Announces New Agreements with DaVita 2
... Isis Pharmaceuticals,Inc. (Nasdaq: ISIS ) announced ... from a randomized Phase 2 clinical trial of,OGX-011 ... arm"),compared to docetaxel and prednisone alone ("the control ... cancer. The current 10.6,month median overall survival ...
... DIEGO, Dec. 3 Vical Incorporated,(Nasdaq: VICL ... with EIP,Eczacibasi Ilac Pazarlama A.S. (EIP) for sales and ... and the Turkish,Republic of Northern Cyprus. EIP has agreed ... to pay Vical upfront and milestone payments,plus a specified ...
Cached Medicine Technology:Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 2Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5
... The BiPAP Pro with Bi-Flex bi-level ... time that the BiPAP Pro takes to ... includes Digital Auto-Trak Sensitivity™ which automatically triggers ... expiratory pressures based on the patients breathing ...
... Gradient Lipoprotein Electrophoresis System (PGGE) is ... as low density lipoproteins (LDL) and ... particle size using nondenaturing pore gradient ... PAGE and short DNA sequencing runs. ...
... The Lipoprint System is a high resolution ... routinely tested by other methods. The test procedure ... than three hours. Any abnormal value is clearly ... the highly atherogenic, small dense LDL in red ...
... This control monitors spinal fluid analyte methods ... Fluid Control is packaged in dropper-tip bottles ... the need for pipets and minimizing waste. ... most major chemistry analyzers and nephelometers: Abbott ...
Medicine Products: